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in restrictive transfusion practices and determine whether any variation
in transfusion practices was associated with patient’s demographic (age,
gender, race) or clinical characteristics (comorbidities, length of stay
(LOS)).
METHODS: Hospitalized general medicine patients with a Hb<10g/dL were
eligible for study participation. Patients with sickle cell anemia were excluded.
Transfusion and Hb data were collected from the hospital’s administrative data
mart. Multiple linear regression was used to test the association between receipt
of a transfusion as the dependent variable, and patients demographic (age,
gender, race, ethnicity) and clinical characteristics (Charlson Comorbidity
Index (CCI), LOS) as the independent variables, controlling for patient’s
admission and nadir Hb levels.
RESULTS: 4,096 patients consented to participate, of which 26% received a transfusion. The average age was 60 (±17), 57% were female,
71% were African American, and 95% were non- Hispanic/Latino. The
mean nadir Hb was 7.9g/dL (±1 g/dL). The rate of transfusion was 1%
for patients with a nadir Hb 9-10g/dL, 21% for patients with a nadir Hb
7-8g/dL, and 83% for patients with a nadir Hb<7g/dL. In the regression
model, Hispanic/Latino patients were less likely to receive transfusion
compared to non-Hispanic/Latino patients (β=-0.26, p=0.05), African
American patients were less likely to receive transfusion (β=-2.03,
p<0.01), and patients reporting a race of “other” were more likely to
receive a transfusion (β=1.73, p<0.01), compared to white patients. A
longer LOS (β=0.1, p< 0.01) was also associated with a higher likelihood of receiving a transfusion. There was no association between
transfusion and age, gender, or CCI.
CONCLUSIONS: Within restrictive transfusion ranges the rate of transfusion
differs by race, ethnicity, and LOS. The differences in transfusion by race and
ethnicity are surprising findings, and future work should examine whether
these differences reflect disparities in care.
LEARNING OBJECTIVE #1: Examine variation in restrictive red blood
cell transfusion practices.
LEARNING OBJECTIVE #2: Examine whether variation transfusion practices is associated with patient's demographic or clinical characteristics.
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BACKGROUND: The Health Insurance Portability and Accountability Act
(HIPAA) protects patients by setting limits on who can view and receive their
health information. HIPAA requires adherence to institutional regulations and
forms include legal language that can be confusing to patients. Although
HIPAA forms would ideally be described in detail by study staff, this is not
always feasible, especially for large pragmatic trials. Therefore, we evaluated
the effect of including a HIPAA authorization in mailed survey packets on
study enrollment.
METHODS: Enrollment packets (i.e., consent forms, +/- HIPAA and surveys) were mailed to English and Spanish-speaking seriously ill eligible
patients (i.e. advanced cancer, heart failure, COPD, cirrhosis, renal failure,
ALS, vulnerable elder with comorbidity) as part of a population-based advance
care planning (ACP) pragmatic trial at three University of California Health
Systems. Participants were excluded if clinicians reported the patient had
cognitive impairment or the survey might cause psychological harm. The
Community Advisory Group raised concerns that the 3-page HIPAA form
required by the institution would hinder enrollment. Therefore, we randomized
1/3 of eligible patients to have the HIPAA authorization included in their
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mailed packet and 2/3 to not have it included. Mailed packets included a
self-addressed, stamped envelope and were followed by up to three reminder
phone calls. We compared enrollment rates within 3 months of outreach for the
two groups.
RESULTS: We mailed enrollment packets to 4634 eligible patients; 1544
patients received an enrollment packet that included a HIPAA authorization
form and 3090 patients received an enrollment packet that did not. Patients
were 51% male, 63% white, 63% were > 70 years old, and 10% were Spanish
speaking; demographic characteristics were similar between the two groups.
There was no difference in rates of telephone follow up between the two
groups. Patients randomized to receive the enrollment packet without the
HIPAA form were significantly more likely to enroll in the study (13.9% v.
9.8%, p<0.001). For subsequent enrollment (phase 2) of the study, we excluded the HIPAA authorization form from all enrollment packets and met our
enrollment target. Follow-up will be needed to collect HIPAA authorization
forms for enrolled patients.
CONCLUSIONS: Inclusion of HIPAA authorization in mailed enrollment
packets led to lower rates of study enrollment. Although HIPAA forms are
more easily described in person or by phone, this is often too resource intensive
for large pragmatic trials. HIPAA authorization forms must be redesigned to
meet the health literacy needs of patients and to prevent unnecessary barriers to
research enrollment.
LEARNING OBJECTIVE #1: Understand the Health Insurance Portability
and Accountability Act (HIPAA) and its role in protecting patient information.
LEARNING OBJECTIVE #2: Understand how HIPPA authorization form
and how it can have an impact on response rates in clinical trials.
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BACKGROUND: The global pandemic of Coronavirus Disease 2019
(COVID-19) has led to over 80 million confirmed cases worldwide and has
been attributed to nearly 2 million deaths. Remdesivir, an adenosine analog
pro-drug, has shown effectiveness in previous in vitro and clinical studies.
However, most randomized studies are preliminary or are limited by small
sample sizes and conflicting findings. As a result, this meta-analysis of randomized, controlled trials (RCTs) was performed to compare intravenous
remdesivir to control in patients hospitalized for COVID-19.
METHODS: A comprehensive literature search of EMBASE, PubMed,
Clarivate Web of Science, and clinical trial registries such as Clinicaltrials.gov
and the World Health Organization International Clinical Trials Registry
Platform. The titles and abstracts of eligible studies were reviewed independently by two authors according to inclusion-exclusion criteria established a
priori. A third author resolved the disputes. A second round of screening by indepth full-text review was then performed. A total of two randomized controlled trials met criteria for inclusion into quantitative synthesis. The primary
outcome was clinical improvement as indicated by a reduction in ordinal scores
based on patient clinical status. Secondary outcomes included mortality rate
and adverse events. Standardized mean differences (SMD) and 95% Confidence Intervals (CI) were used for continuous outcomes. Odds ratios (OR) and
95% CIs were used for dichotomous outcomes. The significance level was set
at 0.05.
RESULTS: This meta-analysis analyzed data from 1,295 patients from 70
clinical sites included in 2 RCTs. Remdesivir was administered as a 200 mg
loading dose on Day 1 followed by 100 mg maintenance doses on Days 2-10.
Remdesivir significantly reduced ordinal scores (2.4 ± 1.7 vs 2.8 ± 1.9, SMD =
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-0.21, 95% CI = -0.33 to -0.09, p < 0.001), indicating clinical improvement,
and significantly reduced mortality (6.8% vs 10.2%, OR = 0.62, 95% CI = 0.41
to 0.94, p = 0.02). The use of remdesivir did not significantly increase anemia,
acute kidney injury, cardiac arrest, deep vein thrombosis, pulmonary embolism, respiratory failure, or septic shock (all ps > 0.05).
CONCLUSIONS: The findings of this meta-analysis suggest that intravenous
remdesivir significantly improves clinical status and reduces mortality in
patients with COVID-19. Moreover, remdesivir appears to be well-tolerated
among hospitalized patients. Further studies are needed to complete the sideeffects profile of the drug as well as optimize dosing, timing, and mode of
delivery. Clinicians should decide whether to administer remdesivir based on
the highest level of evidence available in the literature.
LEARNING OBJECTIVE #1: Recognize whether intravenous remdesivir
improves clinical status.
LEARNING OBJECTIVE #2: Recognize whether intravenous remdesivir
affects mortality rates compared to control.
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BACKGROUND: The WHO defines anemia in females as a hemoglobin
(Hb)<12g/dL and in men as a Hb<13g/dL. These different Hb cutoffs for
defining anemia represent well established differences in normal baseline Hb
concentration between females and males. There are also differences in the
prevalence of anemia in females and males over the life course. Despite these
known differences in baseline Hb concentration and rates of anemia, there is
little data describing whether females and males may also differ in their
tolerance of anemia symptoms, such as fatigue. This is important because if
either males or females have higher anemia-related fatigue levels, then using
the same Hb threshold to transfuse all hospitalized patients may not be the
optimal management for either sex. Importantly, the RCT’s that have informed
restrictive transfusion practices have not reported on sex differences in baseline
Hb levels or how such differences may impact transfusion thresholds with
respect to patients’ symptoms. The purpose of this study was to measure the
fatigue levels of hospitalized patients with anemia, and to test for differences in
the anemia-related fatigue levels of females and males.
METHODS: From 7/2017-2/2020, hospitalized general medicine patients
with a Hb<10g/dL were approached for consent. Patient’s fatigue was measured using the Patient-Reported Outcome Measurement Information System
Fatigue instrument. Patients’ Hb values and clinical data were abstracted from
hospital administrative data. Multiple linear regression was used to test the
association between fatigue as the dependent variable, patients’ sex as the
primary predictor variable, controlling for age, race, ethnicity, nadir Hb level,
Charlson Comorbidity Index, receipt of a transfusion, and length of stay
(LOS).
RESULTS: 1,931 patients consented and 58% were female. Females were
older than males (58 vs. 56, p=0.01). There was a higher percentage of African
American females than males (76% vs 66%), and a lower percentage of white
females compared to white males (46% vs 54%) (p<0.01). Females had a
shorter LOS (9 vs. 10 days, p<0.01) and higher fatigue levels at admission (27
vs 24, p<0.01) compared to males. There were no other differences in baseline
characteristics between males and females with respect to ethnicity, nadir Hb
(7.7g/dL), receipt of a transfusion (31%), or number of comorbidities. In the
regression model, controlling for the above characteristics females had clinically significant higher fatigue levels than did males (β=3.0, p<0.01).
CONCLUSIONS: Hospitalized female patients have higher anemiarelated fatigue levels than do hospitalized male patients. This difference
in fatigue levels may represent different tolerances to anemia and should
be further examined to work determine whether different transfusion
thresholds may mitigate the effects of anemia on fatigue for females
and males.
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LEARNING OBJECTIVE #1: To measure fatigue leves in hospitalized
patients with anemia
LEARNING OBJECTIVE #2: To compare fatigue levels between hospitalized men and women with anemia
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BACKGROUND: Recent data suggest that prescription opioids (PO) may
increase cardiovascular disease (CVD) risk. Compared to those without HIV,
people with HIV have higher risk for CVD and are more likely to have chronic
pain for which they receive PO and at higher doses. We assessed the association of outpatient PO with incident CVD in the Veterans Aging Cohort Study
(VACS).
METHODS: VACS, a national cohort of Veterans with and without HIV,
were eligible at their first clinic visit on or/after 4/1/2003 (index date). Patients
were excluded if, in the year after index date (baseline period), they had: died,
an opioid use disorder diagnostic code, more than minimal PO receipt (>14
days PO or >100mg average morphine-equivalent daily dose [MEDD]), or
severe illness (VACS Index >100). The primary exposures of interest, PO
receipt and total MEDD,were determined in the 3 years after baseline period.
Follow-up for incident CVD began at the end of the opioid exposure window
among those free of CVD and cancer. We used Cox proportional hazards
regression to estimate hazard ratios (HR) with inverse probability weighting to
balance confounders by probability of PO receipt. Models were adjusted for
covariates assessed at the index date: CVD risk factors, HIV, pain intensity
rating, VACS Index, hepatitis C (HCV), alcohol/cocaine use disorder, depression, antidepressant receipt.

RESULTS: Of 38,024 participants, 40% received any PO during the three
year period. Median age was 48 years. The sample was 97% male, 49% black,
and 48% current smokers. HIV, HCV, and diabetes mellitus prevalence were
28%, 5%, and 12% respectively. Alcohol use disorder was greater among those

